Durvalumab in urothelial cancers

Expert Review of Anticancer Therapy
Pernelle LavaudChristophe Massard

Abstract

Urothelial bladder cancer is one of the most predominant malignancies worldwide with a poor prognosis when presented at an advanced or metastatic stage. Improving the therapeutic landscape in this setting has been an unmet medical need. Palliative cisplatin-based chemotherapy is currently the standard of care in first line therapies, but many patients are ineligible and few alternative therapies exist. Moreover second-line chemotherapy has minimal activity. Recently, immune-checkpoint inhibitors have shifted the therapeutic armamentarium of bladder cancer and it is now necessary to redesign the therapeutic paradigm. Areas covered: In this article, we focus on the development of durvalumab and provide an overview of the safety, activity, efficacy and future perspectives of this drug in urothelial carcinoma. Expert commentary: Durvalumab is a well-tolerated drug and demonstrated major and durable response in advanced bladder cancer. Combinations with durvalumab will probably emerge as promising therapeutic strategies for the treatment of urothelial carcinoma. Further research efforts are needed to identify predictive biomarkers of response to immune-oncology agents.

References

Feb 1, 1988·The Journal of Urology·T L RatliffW J Catalona
Sep 1, 1993·The Journal of Urology·T L RatliffW J Catalona
Apr 3, 1998·Lancet·J E Banatvala
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V LorussoM De Lena
May 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C N SternbergUNKNOWN European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group
Jul 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans von der MaaseMichael Arning
Jun 13, 2009·Lancet·Donald S KaufmanAdam S Feldman
Aug 19, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joaquim BellmuntHans von der Maase
Aug 16, 2013·Nature·Ludmil B AlexandrovMichael R Stratton
Feb 5, 2014·Nature Reviews. Urology·Gil Redelman-SidiBernard H Bochner
Aug 7, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BellmuntUNKNOWN ESMO Guidelines Working Group
May 7, 2015·Cancer Immunology Research·Ross StewartMatthew McCourt
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Jan 9, 2016·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
May 4, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rita NandaLaurence Buisseret
Jun 9, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe MassardNeil H Segal
Jul 3, 2016·European Urology·Sebastien AntoniFreddie Bray
Jul 5, 2016·European Urology·J Alfred WitjesMaria J Ribal
Jul 15, 2016·The Oncologist·Valerie LeeLuis A Diaz
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison
Dec 4, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Fred R HirschKeith M Kerr
Feb 18, 2017·The New England Journal of Medicine·Joaquim BellmuntUNKNOWN KEYNOTE-045 Investigators
Mar 23, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joshua BaumlRobert Haddad
May 18, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carin R EspenschiedHeather Hampel
Sep 9, 2017·The New England Journal of Medicine·Scott J AntoniaUNKNOWN PACIFIC Investigators
Sep 12, 2017·The New England Journal of Medicine·Jedd D WolchokJames Larkin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Expert Review of Anticancer Therapy
Nora SundahlPiet Ost
Expert Review of Anticancer Therapy
Min Yuen Teo, Jonathan E Rosenberg
Expert Review of Clinical Pharmacology
Michael Crist, Arjun Balar
Expert Opinion on Emerging Drugs
Kerwin CumberbatchBenjamin A Gartrell
© 2022 Meta ULC. All rights reserved